Copyright
©2011 Baishideng Publishing Group Co.
World J Gastroenterol. Aug 14, 2011; 17(30): 3526-3530
Published online Aug 14, 2011. doi: 10.3748/wjg.v17.i30.3526
Published online Aug 14, 2011. doi: 10.3748/wjg.v17.i30.3526
Table 3 HBV DNA levels during ADV monotherapy according to emergence of ADV-resistant mutations in LAM-resistant patients
| HBV DNA level | ADV resistanceat week 96 (n = 14) | No ADV resistanceat week 96 (n = 63) | P value |
| Baseline (log10 IU/mL, mean ± SD) | 7.1 ± 0.7 | 6.8 ± 1.0 | 0.245 |
| Month 3 (log10 IU/mL, mean ± SD) | 4.2 ± 1.6 | 3.1 ± 1.6 | 0.027 |
| Month 6 (log10 IU/mL, mean ± SD) | 4.1 ± 1.4 | 2.7 ± 1.6 | 0.002 |
| Month 12 (log10 IU/mL, mean ± SD) | 3.9 ± 1.3 | 2.4 ± 1.5 | 0.002 |
- Citation: Sinn DH, Lee HI, Gwak GY, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH. Virological response to adefovir monotherapy and the risk of adefovir resistance. World J Gastroenterol 2011; 17(30): 3526-3530
- URL: https://www.wjgnet.com/1007-9327/full/v17/i30/3526.htm
- DOI: https://dx.doi.org/10.3748/wjg.v17.i30.3526